[go: up one dir, main page]

AR106332A1 - Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona - Google Patents

Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona

Info

Publication number
AR106332A1
AR106332A1 ARP160103122A ARP160103122A AR106332A1 AR 106332 A1 AR106332 A1 AR 106332A1 AR P160103122 A ARP160103122 A AR P160103122A AR P160103122 A ARP160103122 A AR P160103122A AR 106332 A1 AR106332 A1 AR 106332A1
Authority
AR
Argentina
Prior art keywords
dihydroisoquinolin
methylbutyl
hydroxy
methyl
crystalline form
Prior art date
Application number
ARP160103122A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR106332A1 publication Critical patent/AR106332A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Una forma cristalina caracterizada porque es de 2-(2,6-diclorofenil)-1-[(1S,3R)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1H)-il]etanona. Reivindicación 2: La forma cristalina de 2-(2,6-diclorofenil)-1-[(1S,3R)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1H)-il]etanona de conformidad con la reivindicación 1, caracterizada por un patrón de difracción en polvo de rayos-X usando radiación CuKa que tiene un pico de difracción en ángulo de difracción 2-q de 9.15º en combinación con uno o más picos seleccionados a partir del grupo que consiste de 19.4º, 16.1º, y 16.6º; con una tolerancia para los ángulos de difracción de 0.2 grados.
ARP160103122A 2015-10-23 2016-10-13 Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona AR106332A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562245391P 2015-10-23 2015-10-23

Publications (1)

Publication Number Publication Date
AR106332A1 true AR106332A1 (es) 2018-01-03

Family

ID=57233858

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103122A AR106332A1 (es) 2015-10-23 2016-10-13 Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona

Country Status (13)

Country Link
CN (1) CN108137506A (es)
AR (1) AR106332A1 (es)
AU (1) AU2016341115A1 (es)
CA (1) CA2999332A1 (es)
DO (1) DOP2018000103A (es)
EA (1) EA201890525A1 (es)
EC (1) ECSP18030976A (es)
IL (1) IL257872A (es)
MX (1) MX2018004794A (es)
PE (1) PE20181296A1 (es)
PH (1) PH12018500859A1 (es)
TW (1) TW201725199A (es)
WO (1) WO2017070068A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI725408B (zh) * 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
MD3897578T2 (ro) 2018-12-18 2025-04-30 Lilly Co Eli Regimuri de dozare pentru utilizarea LY3154207 în tratamentul tulburărilor dopaminergice ale SNC
TWI825323B (zh) * 2019-06-18 2023-12-11 美商美國禮來大藥廠 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物
AU2022234744B2 (en) * 2021-03-08 2025-06-26 Eli Lilly And Company Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis
AU2022234226B2 (en) * 2021-03-09 2025-08-14 Eli Lilly And Company Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression
CN113264926A (zh) * 2021-05-31 2021-08-17 东北林业大学 一种牡荆素与利血平的共晶及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236934A (en) * 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
EP2125741A1 (en) * 2007-03-01 2009-12-02 Janssen Pharmaceutica, N.V. Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor
US20120252853A1 (en) * 2011-04-01 2012-10-04 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
JO3316B1 (ar) * 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل

Also Published As

Publication number Publication date
PE20181296A1 (es) 2018-08-07
CA2999332A1 (en) 2017-04-27
AU2016341115A1 (en) 2018-04-12
CN108137506A (zh) 2018-06-08
DOP2018000103A (es) 2018-10-31
MX2018004794A (es) 2018-06-19
ECSP18030976A (es) 2018-05-31
TW201725199A (zh) 2017-07-16
PH12018500859A1 (en) 2018-10-29
EA201890525A1 (ru) 2018-09-28
WO2017070068A1 (en) 2017-04-27
IL257872A (en) 2018-06-03

Similar Documents

Publication Publication Date Title
AR106332A1 (es) Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona
GEP20197011B (en) Heteroaryl compounds for kinase inhibition
EA201791305A1 (ru) Конденсированные пиримидины для лечения вич
MX2018011792A (es) Compuestos de pirrolotriazina como inhibidores de tyro3, axl y mer (tam).
AR101403A1 (es) (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridin-3-carboxamida, su purificación para su uso como principio activo farmacéutico, un procedimiento para su preparación y su empleo en el tratamiento de enfermedades cardiovasculares
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
MX375970B (es) Compuestos de triazolopirimidina y usos de los mismos.
EA201791304A1 (ru) Производные изохинолина для лечения вич
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
NI201800042A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1
PE20171105A1 (es) Formas solidas de un inhibidor ask1
CL2011002267A1 (es) Compuesto derivado de pirazolopiridina sustituida, inhibidor de la quinasa lrrk2; procedimiento de preparacion de dicho compuesto; composicion farmaceutica; combinacion farmaceutica; uso del compuesto para prevenir o tratar un trastorno seleccionado de cancer y enfermedades neurodegenerativas.
CL2014001049A1 (es) Compuestos derivados de purina sustituida, inhibidores de mtor; composicion farmaceutica; combinacion farmaceutica; uso para el tratamiento o prevencion del cancer, un trastorno neurodegenerativo o una enfermedad oftalmologica.
IL279101A (en) Salts of spiafatrin are accepted in pharmacies
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
AR095435A1 (es) Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (s)-quinuclidin-3-ilo
EA201790276A1 (ru) Новые имидазопиридазиновые соединения и их применение
MX2015015073A (es) Sintesis de 3-(5-amino-2-metil-4-oxoquinazolin-3(4h)-il)piperidin- 2,6-diona.
BR112015023351A2 (pt) forma cristalina de sovaprevir, composição farmacêutica, e, método para tratar um distúrbio
PT3643717T (pt) Compostos de pirrolo triazina substituídos na posição 7 ou sais farmaceuticamente aceitáveis dos mesmos e método de preparação dos mesmos e utilizações dos mesmos
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
MX2017014830A (es) Metodo para tratar las enfermedades roya del cafe, mancha negra de los citricos, sarna de los citricos y sigatoka negra de la banana.
ZA201802399B (en) Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer
AR099082A1 (es) Formas sólidas de tenofovir
MX2017016533A (es) Metodo para tratar glomeruloesclerosis focal y segmentaria primaria.

Legal Events

Date Code Title Description
FB Suspension of granting procedure